NCT00973037Unknown不适用
Impact of CYP2D6 Genotype on the Clinical Effects of Tamoxifen Using With Samples From Prospective Randomized Multicenter Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 922
- 试验地点
- 1
- 主要终点
- Disease-free survival(DFS)
研究概览
简要总结
The purpose of this study is to investigate the impact of CYP2D6 Genotype on the clinical effects of tamoxifen using with samples from prospective randomized multicenter study(ASTRRA).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The patient must sign the informed consent form.
- •The patient must sign the informed consent of genotype screening test.
- •The patient must be between 18 years old and 45 years old who can make a decision independently.
- •Patients must have undergone excision of the primary breast mass, proven histologically to be invasive breast adenocarcinoma.(The type of mastectomy performed, number of axillary nodes removed, number of axillary nodes found positive, and tumor size must be included on the CRFs. For patients who have more than one discrete tumor masses should be measured and reported on the CRFs.)
- •Patients must be within 3 months after the last cycle of chemotherapy.
- •Patients must have the history of normal menstruation prior to the start of chemotherapy.
- •Stage I, II or III
- •Woman, less than or equal to 45 years of age
- •The test result of the estrogen receptor is positive.
- •WHO performance status 0, 1 or
- •Patients who were treated with cytotoxic chemotherapy in pre or post surgery. Permissible prior chemotherapy; currently locally available and approved standard chemotherapy in the adjuvant or neoadjuvant setting: e.g., AC(Doxorubicin/cyclophosphamide) followed by taxane, AC(Doxorubicin/cyclophosphamide), TA(Docetaxel/ Doxorubicin), FAC(5-fluorouracil/ doxorubicin / cyclophosphamide) or others.
- •Adequate hematological function defined by hemoglobin 10g/dl, neutrophil count 1.5 X 10 9/L and platelets 100 X 10 9/L.
- •Adequate hepatic function defined by AST and ALT 2.5 X upper limit of normal. Alkaline phosphatase 5 X upper limit of normal, unless bone metastases in the absence of liver disease. Renal function adequate defined by creatinine < 175 mmol/L.
排除标准
- •The test result of the estrogen receptor is negative or unknown.
- •Patients with the history of hysterectomy or oophorectomy.
- •Sarcomas or squamous cell carcinomas of the breast are not eligible.
- •Patients with malignancies(other than breast cancer) within the last 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell/squamous cell carcinoma of the skin.
- •Investigational drugs given within the previous 4 weeks.
- •Patients with thrombocytopenia (platelets < 100 X 10 9/L or on anti-coagulant therapy(contra-indicated due to risk of bleeding with i.m. injection of Zoladex).
- •Patients treated with CMF(cyclophosphamide/methotrexate/5-fluorouracil) as prior chemotherapy.
- •Patients who are pregnant or lactating are ineligible.
研究组 & 干预措施
CYP2D6
CYP2D6 genotype
干预措施: Tamoxifen (Drug)
结局指标
主要结局
Disease-free survival(DFS)
时间窗: 5years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Genotyping and Phenotyping of CYP2D6 Breast Cancer Patients on TamoxifenBreast Cancer FemaleNCT03504631Trisakti University117
终止
2 期
Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of TamoxifenMetastatic DiseaseBreast CancerNCT00532454National Cancer Center, Korea21
已完成
不适用
Cohort Study to Assess the Impact of CYP2D6 Genotype on the Efficacy ofClomipheneN97.9Female infertility, unspecifiedDRKS00010070Robert Bosch Gesellschaft für Medizinische Forschung mbH161
招募中
1 期
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PKDrug-Drug InteractionNCT05789173Indiana University60
Unknown
不适用
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of TamoxifenBreast CancerNCT03582865Assiut University100